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Abstract 
The need for new treatments for the neglected tropical diseases African sleeping sickness, Chagas 
disease and Leishmaniasis remains urgent with the diseases widespread in tropical regions, affecting the 
world’s very poorest. We have previously reported bis-tetrahydropyran 1,4-triazole analogues designed 
as mimics of the annonaceous acetogenin natural product chamuvarinin, which maintained trypanocidal 
activity. Building upon these studies, we here report related triazole compounds with pendant 
heterocycles, mimicking the original butenolide of the natural product. Analogues were active against T. 
brucei, with a nitrofuran compound displaying nanomolar trypanocidal activity. Several analogues also 
showed strong activity against T. cruzi and L. major. Importantly, select compounds gave excellent 
selectivity over mammalian cells with a furan-based analogue highly selective while remaining active 
against all three cell lines, thus representing a potential lead for a new broad spectrum kinetoplastid 
inhibitor. 
  
1. Introduction 
 
As defined by the World Health Organization, a neglected tropical disease (NTD) is a tropical infection 
that affects millions of people worldwide1 but has seen inadequate investigation into treatment.2,3 This is 
principally due to the limited financial incentive in treating such conditions, which is linked to their 
prevalence in developing countries where healthcare spending is low and health infrastructure is poor. 
Three such diseases are African sleeping sickness,4 Chagas disease5 and Leishmaniasis,6 spread by the 
related kinetoplastid parasitic causative agents Trypanosoma brucei, Trypanosoma cruzi and Leishmania 
spp, respectively. These parasites are present in tropical regions across the world; T. brucei in sub-
Saharan Africa, T. cruzi in South America and increasingly in North America7 and Leishmania 
throughout the tropics and sub-tropics.8 All three diseases share a genetic similarity and treatments 
developed for one specific disease have sometimes proved effective in treating another e.g. nifurtimox 
was originally developed for Chagas disease but has subsequently found application as a combination 
therapy for African sleeping sickness.9,10 
 
The tropical plants of the Annonaceae species have long been known for their therapeutic properties, 
with the crude extracts of fruits, leaves, roots and bark used in traditional medicinal practices to treat a 
range of tropical diseases.11 Interest in this plant species as a source of potential new drugs intensified 
with the discovery of a family of fatty acid derived natural products, collectively termed the 
Annonaceous acetogenins, which now number in excess of 400.12 Structurally, the acetogenins are 
C32/C34 fatty acids generally characterised by a central array of one to three tetrahydrofuran (THF) 
rings with flanking hydroxyl groups and appended with a terminal butenolide ring system as found in 
squamocin 1 and senegalene 2 (Figure 1).13 In contrast the tetrahydropyran (THP) ring system is less 
common and only seven acetogenins bear this motif including chamuvarinin 3. Members of this family 
of secondary metabolites are often highly cytotoxic displaying sub-nanomolar activity towards human 
cancer cell lines.14  
 
Figure 1 Annonaceous acetogenins with known anti-kinetoplastid activity 
 
 
By contrast, the biological evaluation of acetogenins for the treatment of NTD has thus far been 
remarkably limited considering the wide scale use across sub-Saharan Africa of acetogenin-containing 
crude plant extracts to treat African sleeping sickness.15 Studies to date have primarily focussed on the 
phytochemical study of extracts from Annonaceae species for trypanocidal activity, with efforts focused 
on T. brucei,16 though select compounds such as squamocin 1 have shown encouraging preliminary 
activity against T. cruzi and Leishmania strains.17 In 2003 Laurens et al. reported that the root and bark 
extracts of Uvaria chamae are active towards T. brucei, which subsequently led to the isolation of 
chamuvarinin 3.18 Chamuvarinin is one of only seven acetogenins to contain a tetrahydropyran ring 
system and the only acetogenin to contain an all adjacently linked bis-THF-THP core ether ring system. 
In 2011, we reported the first total synthesis of chamuvarinin thereby establishing its absolute 
stereochemical structure. In addition our synthetic material displayed single figure micromolar activity 
towards the bloodstream form of T. brucei brucei, albeit with low selectivity over the HeLa human cell 
line.19 
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We built on these studies by designing a series of analogues inspired by chamuvarinin 3 that maintained 
T. brucei activity commensurate to that of the natural product (Figure 2).20 These analogues simplified 
the structure of chamuvarinin principally by replacing the central THF ring of the tricyclic core with a 
1,4-triazole. This allowed rapid assembly of enantiomerically enriched THP building blocks via click 
chemistry, producing initial lead 4, which displayed low (1.8 µM) trypanocidal activity against 
bloodstream form T. brucei. From this starting point, other features of the natural product were 
introduced, in particular the pendant butenolide, the orientation of which (‘left- or right-hand side’ as 
drawn) was critical to activity with 6 maintaining activity, while 5 was completely inactive. These 
results encouraged us to explore alternatives to the butenolide, principally on the azide, or ‘left-hand 
side’ of the molecule. Inspired by the work of Yamashita and co-workers, we have focused on simple 
aromatic heterocycles that were found to act as effective butenolide mimics.21 Our phenotypic screening 
program has now expanded to the other NTD parasite cell lines, T. cruzi and Leishmania major, so new 
potential inhibitors were evaluated against all three protozoa.22  
 
 
Figure 2 Directionality in our triazole based T. brucei inhibitors 
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2. Results and Discussion 
 
2.1 Synthesis 
 
In order to rapidly access analogues with varying head groups, we targeted a THP precursor with an 
extended chain already present. Beginning from alcohol 7, mesylation followed by SN2 reaction with 6-
((triisopropylsilyl)oxy)hexan-1-ol generated alkene 8 (Scheme 1).23 After racemic epoxidation, kinetic 
resolution with Jacobsen salen catalyst produced chiral epoxide 9 with 95% ee.24 Ring-opening with 
homoallyl magnesium bromide followed by epoxidation of the resulting double bond and in situ 
cyclisation generated THP alcohol 10 along with its diastereomeric pair (not shown) which were readily 
separated chromatographically. After conversion of the alcohol to azide 11 with DPPA, a “click” 
reaction with alkyne 12 generated the key THP-triazole-THP tricyclic core. Straightforward acidic 
deprotection then gave alcohol 13.  
 
 
Scheme 1 Synthesis of starting material: a) MsCl, NEt3, CH2Cl2, 0 °C → RT; b) NaH, 6-((triisopropylsilyl)oxy)hexan-1-ol, 
THF, reflux, 91% (2 steps); c) 3-chloroperbenzoic acid, CH2Cl2, 0 °C → RT, 83%; d) 0.6 mol% (S,S)-Co-salen catalyst, 6 
mol% AcOH, H2O, THF, 49%; e) CH2CHCH2CH2MgBr, CuI, THF, -40 °C → RT, 84%; f) 3-chloroperbenzoic acid, CH2Cl2, 
0 °C → RT; then (±)-camphorsulfonic acid (20 mol%), RT, 43% syn, 38% anti; g) diphenylphosphoryl azide, K2CO3, MeOH, 
RT, 83%; h) CuSO4.5H2O, Na ascorbate, H2O, t-BuOH, RT, 89%; i) (±)-camphorsulfonic acid (20 mol%), CH2Cl2:MeOH, 
RT, 88%. 
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Alcohol 13 served as a key point for derivatisation. Functional group interconversion of the alcohol via 
the azide provided amine 16 (Scheme 2). This then allowed the complete set of head group analogues 
17-32 to be accessed via straightforward coupling with the appropriate acid in generally good yields. 
Targeted analogues focused on oxygen, nitrogen and sulfur containing five-membered aromatic 
heterocycles including furan, pyrrole and thiophene derivatives.21 For comparison with these compounds, 
benzylation of the free alcohol of 13 gave fully protected 14 while hydrogenation generated diol 15.  
 
 
Scheme 2 Synthesis of analogues: a) MsCl, NEt3, CH2Cl2, 0 °C → RT, 87%; b) NaH, benzyl alcohol, THF, reflux, 33%; c) 
H2, Pd(OH)2, EtOH, RT, 59%; d) NaN3, DMF, 40 °C, 74%; e) PPh3, THF, RT then H2O, 83%; f) carboxylic acid, N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, N-dimethylaminopyridine, CH2Cl2, RT. 
 
In an effort to separate the influence of the head group from that of the tricyclic core, a selection of 
heterocycles with simple alkyl chains were synthesised as controls (Scheme 3). Amide coupling of a 
pyrazole acid, furoic acid and 5-nitrofuroic acid with a simple amino alcohol gave the corresponding 
alcohols, which were then capped using trimethyloxonium tetrafluoroborate to give methylated 
analogues 33, 34 and 35.  
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hydrochloride, N-dimethylaminopyridine, CH2Cl2, RT; b) Me3O•BF4, CH2Cl2, 0 °C → RT. 
 
2.2 Biological Testing 
 
We began our biological screening by testing relevant synthetic intermediates and compounds without 
head groups to give a baseline for activity (Table 1). All analogues were screened against our 
kinetoplastid cell lines: T. brucei, T. cruzi and L. major as well as the human HeLa cell line which we 
used to assess potential selectivity of our analogues over mammalian cells.25 All analogues were active 
at low micromolar concentrations in T. brucei, with the exception of diol 15,26 consistent with the 
activity we have observed for the tricyclic core of our molecules (entry 3). In T. cruzi, 13 and 16 showed 
moderate activity, while di-benzyl 14 and diol 15 analogues were essentially inactive. In L. major, 
hydroxyl terminated 13 gave best inhibition at 12.4 µM (entry 1) with all other analogues less active, 
though amine 16 had moderate 19.8 µM activity (entry 4). Significantly, analogues showed HeLa 
inhibition comparable to the other lines tested indicating a general lack of selectivity for parasite cells 
over mammalian cells. 
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Table 1 Synthetic intermediates and non-head group analogues (*Toxicity likely due to biophysical effect, rather than on-
target interaction) 
 
With selectivity a primary concern, an initial set of our amide analogues was screened against the same 
cell lines (Table 2). Select compounds were also screened against the Vero cell line as a secondary, non-
cancerous mammalian cell line to further assess selectivity over mammalian cells. For T. brucei, 
heterocycle incorporation was well tolerated with all analogues tested falling within a narrow range of 
3.8 to 8.4 µM, the best of these being 2-furan 18 (entry 2). The results in T. cruzi displayed significantly 
more variation with furan 18 the most active compound at 8.0 µM inhibition (entry 2). Interestingly, any 
change of the heteroatom in the simple heterocycles away from oxygen removed activity, as did a 
change to 3-hetero substitution (entries 3-7). By contrast, 1,3-azoles displayed modest activity, the best 
being thiazole 24 (entry 8) and methyl oxazole 26 (entry 10). 3-Hetero substitution was tolerated in L. 
major (entries 6 and 7), as were 1,3-azoles (entries 8-10) but again the best compound was furan 18 at 
7.8 µM (entry 2).  
 
Most pleasingly, the majority of analogues were essentially inactive against the HeLa cell line, with the 
exception of oxazoles 25 and 26 (entries 9 and 10). This implies potential added selectivity for parasite 
over mammalian cells, an essential criterion for any new therapeutic treatment. Furthermore, almost 
identical results to HeLa were obtained with selected analogues against Vero cells, with lead compound 
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18 showing no activity against both of these mammalian cell lines. The broad-spectrum anti-parasitic 
activity and selectivity of 18 was highly encouraging and led us to explore additional furan head groups 
below.27 
  
 
Table 2 Initial set of inhibitors 17-27 (*Toxicity likely due to biophysical effect, rather than on-target interaction) 
 
We next curated a series of analogues in order to probe both steric and electronic variation of the 
pendant furan (Table 3). In T. brucei, methyl substitution (entries 2-4) was tolerated across the furan 
ring without loss of activity, as was a moderately electron withdrawing chloride group (entry 5). 
Introduction of a nitro group in 32 led to a step-change improvement in activity, down to 37.3 nM (entry 
6). By contrast, in T. cruzi any perturbation of the furan was detrimental to activity with all analogues 
greater than 100 µM, the only exception being nitro compound 32 with slightly improved activity (entry 
6). For L. major, 5-methyl and 5-nitro substitution was tolerated (entries 2 and 6) but changing the 
substitution position or adding electron-withdrawing groups gave reduced activity (entries 3-5). The 
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compounds showed generally moderate to no activity against HeLa with nitro compound 32 once again 
the exception at 0.38 µM. 32 was also examined in Vero with an EC50 of 4.5 µM. 
Although the results for 32 are encouraging, particularly the excellent activity in T. brucei, it should be 
noted that 5-nitroheterocycles are well known to have activity against T. brucei and T. cruzi and thus we 
were conscious the increased activity of 32 may result from the nitrofuran head group, with the tricyclic 
core possibly only helping in cellular localisation.3,28 We thus accessed pyrazole 33, furan 34 and 
nitrofuran 35 that contain a head group and a simple alkyl chain only to aid solubility. We were pleased 
to see that 33 and 34 were essentially inactive in all lines tested- indicating the primacy of the tricyclic 
core in these analogues (entries 7 and 8). As expected, nitrofuran 35 showed activity in all cell lines, 
with the results in T. cruzi, L. major and HeLa broadly in line with those of 32 (compare entries 6 and 8). 
However, although activity was sub-micromolar in T. brucei, this nonetheless represents an almost a 20-
fold reduction in activity from 32 to 35, suggesting a synergistic effect between the tricyclic core of 32 
and the nitrofuran head group. The exact nature of this effect remains under investigation. 
  
  
 
Table 3 Furan based inhibitors 18, 28-35 (*Toxicity likely due to biophysical effect, rather than on-target interaction) 
 
3. Conclusion 
 
In summary, we have accessed a new series based upon the previously established THP-triazole-THP 
motif incorporating a series of heterocycles in a position to mimic the butenolide core of our original 
natural product inspiration, chamuvarinin. These analogues displayed significant activity in a range of 
kinetoplastid parasite cell lines; T. brucei, T. cruzi and L. major, with some analogues also showing 
selectivity over mammalian cell lines Vero and HeLa. Two compounds stand out from the screen: the 
furan 18 displayed low micromolar activity in all parasite cell lines with excellent selectivity and thus 
represents a starting point for a potential broad spectrum kinetoplastid inhibitor. Nitrofuran 32 displayed 
nanomolar T. brucei inhibition, with promising selectivity over human cell lines. Our current efforts are 
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focused on further SAR studies of these key compounds, including expansion into the other heterocyclic 
linker series currently under investigation within our team.  
 
4. Experimental 
 
4.1 Chemistry  
 
Synthetic details for tested compounds are described below. For details of the synthesis of intermediates, 
see Supporting Information. 
 
4.1.1 General procedure for amide coupling 
 
The appropriate carboxylic acid (34.2 µmol, 2 eq), EDCI.HCl (5.30 mg, 34.2 µmol, 2 eq) and DMAP 
(17.1 µmol, 1 eq) were combined in CH2Cl2 (2 mL) and stirred at RT for 10 min. Amine 15 (10.0 mg, 
17.1 µmol, 1 eq) was added and the resulting mixture stirred at RT overnight. Reaction was, quenched 
by the addition of saturated aqueous NH4Cl solution (5 mL), extracted with EtOAc (3 x 5 mL) and the 
combined organic layers washed with 0.1 M aqueous KOH solution, brine, dried (MgSO4), filtered and 
concentrated in vacuo.  
 
4.2 Compounds 
 
4.2.1 6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexan-1-ol 13 
 
To a solution of 4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1-(((2S,6S)-6-(4-((6-
((triisopropylsilyl)oxy)hexyl)oxy)butyl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazole S6 (1.62 g, 
2.18 mmol) in methanol (15 mL) and CH2Cl2 (15 mL) was added a solution of (±)-CSA (101 mg, 0.440 
mmol) in methanol (5 mL) and the mixture stirred at RT for 48 h. Reaction was quenched by the 
addition of saturated aqueous NaHCO3 (30 mL). The mixture was extracted with CH2Cl2 (3 x 30 mL) 
and the combined organic extracts washed with brine, dried (MgSO4), filtered and concentrated in vacuo. 
Purification by flash column chromatography (60% EtOAc/Hexane) provided alcohol 13 (1.12 g, 88%), 
as a colourless oil. 
Rf 0.17 (50% EtOAc/Hexane);  –19 (c 0.40, CHCl3); IR (ATR) 3406, 2932, 2855, 1734 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.60 (1H, s, HAr), 7.35-7.24 (5H, m, ArH), 4.59 (1H, dd, J = 10.9, 1.8 Hz, 
H1’), 4.48 (2H, s, OCH2Ar), 4.42 (1H, dd, J = 14.0, 3.3 Hz, H1a), 4.19 (1H, dd, J = 14.0, 8.0 Hz, H1b), 
3.67-3.60 (1H, m, H2), 3.61 (2H, t, J = 6.6 Hz, H16), 3.49-3.44 (1H, m, H5’), 3.46 (2H, t, J = 6.6 Hz, H9’), 
3.37 (2H, t, J = 6.7 Hz, H10), 3.36 (2H, t, J = 6.8 Hz, H11), 3.24-3.19 (1H, m, H6), 2.02-1.83 (3H, m, H3a’ 
+ H4), 1.66-1.14 (29H, m, H2’-4’ + H3b + H5 + H6’-8’ + H7-9 + H12-15); 13C NMR (100 MHz, CDCl3) δ 
150.0, 138.8, 128.5, 127.7, 127.6, 122.4, 78.4, 77.8, 76.2, 73.3, 73.0, 71.0, 70.9, 70.5, 62.9, 55.1, 36.4, 
36.2, 32.8, 31.9, 31.3, 31.2, 29.9, 29.8, 29.7, 28.7, 26.1, 25.7, 23.7, 23.1, 22.4, 22.3; HRMS (ESI+) Calc. 
for C34H56O5N3 [M+H]+ 586.4214, found 586.4207. 
 
4.2.2 4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1-(((2S,6S)-6-(4-((6-
(benzyloxy)hexyl)oxy)butyl)tetrahydro-2H-pyran-2-yl)methyl)-1H-1,2,3-triazole 14 
 
To a solution of sodium hydride (6.00 mg of 60% dispersion in mineral oil, 151 µmol) in dry THF (2ml) 
at RT was added benzyl alcohol (15.6 µL, 151 µmol). After 15 min, a solution of 6-(4-((2S,6S)-6-((4-
((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-triazol-1-yl)methyl)tetrahydro-2H-
pyran-2-yl)butoxy)hexyl methanesulfonate S7 (20.0 mg, 30.1 µmol) in dry THF (2 mL) was added and 
the mixture heated at reflux overnight. The mixture was diluted with water (10 mL) and extracted with 
Et2O (3 x 10 mL). The combined organic extracts were washed with brine, dried (MgSO4) and 
concentrated in vacuo. Purification by flash column chromatography (10% Acetone/Hexane) afforded 
ether 14 (6.7 mg, 33%), as a colourless oil. 
 
Rf 0.41 (20% Acetone/Hexane);  –16 (c 0.64, CHCl3); IR (ATR) 2932, 2855, 1724 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.60 (1H, s, HAr), 7.38-7.24 (10H, m, ArH), 4.59 (1H, dd, J = 10.9, 1.8 Hz, H1’), 
4.49 (2H, s, OCH2Ar), 4.48 (2H, s, OCH2Ar), 4.43 (1H, dd, J = 14.0, 3.4 Hz, H1a), 4.19 (1H, dd, J = 
14.0, 8.0 Hz, H1b), 3.67-3.61 (1H, m, H2), 3.50-3.44 (1H, m, H5’), 3.46 (2H, t, J = 6.6 Hz, H16), 3.46 (2H, 
t, J = 6.6 Hz, H9’), 3.37 (2H, t, J = 6.4 Hz, H10), 3.36 (2H, t, J = 6.9 Hz, H11), 3.24-3.19 (1H, m, H6), 
2.03-1.83 (3H, m, H3a’ + H4), 1.66-1.14 (29H, m, H2’-4’ + H3b + H5 + H6’-8’ + H7-9 + H12-15); 13C NMR 
(100 MHz, CDCl3) δ 150.0, 138.8 (2C), 128.5 (2C), 127.7 (2C), 127.6 (2C), 122.4, 78.4, 77.9, 76.3, 73.3, 
73.0 (2C), 71.1, 70.9, 70.6, 70.5, 55.1, 36.4, 36.2, 31.9, 31.4, 31.3, 30.0, 29.9 (2C), 29.8, 28.7, 26.2 (2C), 
23.8, 23.1, 22.3, 22.2; HRMS (ESI+) Calc. for C41H61O5N3Na [M+Na]+ 698.4503, found 698.4481. 
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4.2.3 6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-hydroxybutyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-triazol-1-
yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexan-1-ol 15 
 
To a solution of alcohol 13 (20.0 mg, 34.1 µmol) in EtOH (2 mL) at RT was added Pd(OH)2 on carbon 
(6.50 mg of 20% wt on carbon, 6.82 µmol). The reaction system was purged with H2 and left under a 
positive pressure of H2 overnight. The reaction mixture was filtered through Celite and washed with 
EtOH. The filtrate was concentrated in vacuo and purification by flash column chromatography (EtOAc 
then 3% MeOH/EtOAc) provided diol 15 (10.0 mg, 59%), as a colourless oil. 
Rf 0.24 (EtOAc);  –22 (c 1.0, CHCl3); IR (ATR) 3360, 2932, 2857 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 7.62 (1H, s, HAr), 4.59 (1H, dd, J = 10.9, 1.8 Hz, H1’), 4.44 (1H, dd, J = 14.0, 3.2 Hz, H1a), 
4.20 (1H, dd, J = 14.0, 8.0 Hz, H1b), 3.68-3.60 (1H, m, H2), 3.62 (2H, t, J = 6.3 Hz, H16), 3.61 (2H, t, J = 
6.6 Hz, H9’), 3.53-3.45 (1H, m, H5’), 3.33 (2H, t, J = 6.6 Hz, H10), 3.36 (2H, t, J = 6.5 Hz, H11), 3.24-
3.18 (1H, m, H6), 2.05-1.86 (3H, m, H3a’ + H4), 1.70-1.13 (29H, m, H2’-4’ + H3b + H5 + H6’-8’ + H7-9 + H12-
15); 13C NMR (75 MHz, CDCl3) δ 149.9, 122.4, 78.4, 77.8, 76.2, 73.3, 71.0, 70.9, 62.9, 62.8, 55.1, 36.2 
(2C), 32.8, 32.8, 31.7, 31.4, 31.3, 29.8 (2C), 28.7, 26.1, 25.7, 23.7, 23.1, 22.2, 21.9; HRMS (ESI+) Calc. 
for C27H49O5N3Na [M+Na]+ 518.3564, found 518.3549. 
 
4.2.4 4-[(2S’,6S’)-6’-(4-((6-aminohexyl)oxy)butyl)tetrahydropyran-2-yl]-1-[(2S’’,6S’’)-6’’-(4-
hydroxybutyltetrahydropyran-2-yl)methyl]-1H-1,2,3-triazole 16 
 
To a solution of 4-[(2S’,6S’)-6’-(4-((6-azidohexyl)oxy)butyl)tetrahydropyran-2-yl]-1-[(2S’’,6S’’)-6’’-(4-
hydroxybutyltetrahydropyran-2-yl)methyl]-1H-1,2,3-triazole (251 mg, 0.411 mmol) S7 in THF (4 mL) 
at 0 °C was added PPh3 (162 mg, 0.617 mmol). The reaction mixture was stirred at RT overnight, then 
quenched with water (12 drops) and concentrated in vacuo. Purification by flash column 
chromatography (5% MeOH/1% NEt3/CH2Cl2) provided amine 16 (200 mg, 83%), as a colourless oil. 
Rf 0.55 (10% MeOH/1% NEt3/CH2Cl2);  –21 (c 1.1, CHCl3); IR (ATR) 2931, 2855, 1560, 1454 
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.60 (1H, s, HAr), 7.33-7.27 (5H, m, ArH), 4.59 (1H, dd, J = 11.0, 
1.9 Hz, H1’), 4.49 (2H, s, OCH2Ar), 4.43 (1H, dd, J = 14.0, 3.4 Hz, H1a), 4.19 (1H, dd, J = 14.0, 8.0 Hz, 
H1b), 3.66-3.61 (1H, m, H2), 3.49-3.45 (1H, m, H5’), 3.46 (2H, t, J = 6.6 Hz, H9’), 3.37 (2H, t, J = 6.6 Hz, 
H10), 3.35 (2H, t, J = 6.8 Hz, H11), 3.23-3.19 (1H, m, H6), 2.70 (2H, br s, H16), 2.03-1.86 (3H, m, H3a’ + 
H4), 1.64-1.15 (29H, m, H2’-4’ + H3b + H5 + H6’-8’ + H7-9 + H12-15); 13C NMR (125 MHz, CDCl3) δ 150.0, 
138.8, 128.5, 127.8, 127.6, 122.4, 78.4, 77.8, 76.2, 73.3, 73.0, 71.0, 70.9, 70.5, 55.1, 42.1, 36.4, 36.2, 
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33.5, 31.8, 31.3, 31.2, 30.0, 29.9, 29.8, 28.7, 26.9, 26.2, 23.7, 23.1, 22.3, 22.2; HRMS (ESI+) Calc. for 
C34H57O4N4 [M+H]+ 585.4374, found 585.4358. 
 
4.2.5 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)benzamide 17 
 
The general procedure was followed using benzoic acid (4.20 mg, 34.2 µmol). Purification by flash 
column chromatography (40% EtOAc/Hexane) provided amide 17 (8.7 mg, 74%), as a colourless oil. 
Rf 0.51 (60% EtOAc/Hexane);  –15 (c 0.87, CHCl3); IR (ATR) 3323, 2932, 2855, 1717, 1639, 
1578, 1537 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.76-7.75 (2H, m, H19), 7.60 (1H, s, HAr), 7.50-7.40 
(3H, m, H20 + H21), 7.33-7.24 (5H, m, ArH), 6.22 (1H, br s, NH), 4.59 (1H, dd, J = 11.0, 1.9 Hz, H1’), 
4.48 (2H, s, OCH2Ar), 4.42 (1H, dd, J = 14.0, 3.3 Hz, H1a), 4.19 (1H, dd, J = 14.0, 8.1 Hz, H1b), 3.65-
3.61 (1H, m, H2), 3.49-3.42 (5H, m, H5’ + H9’ + H16), 3.39-3.33 (4H, m, H10 + H11), 3.23-3.19 (1H, m, 
H6), 2.02-1.83 (3H, m, H3a’ + H4), 1.68-1.14 (29H, m, H2’-4’ + H3b + H5 + H6’-8’ + H7-9 + H12-15); 13C 
NMR (125 MHz, CDCl3) δ 167.6, 149.9, 138.7, 134.9, 131.4, 128.7 (2C), 128.5 (2C), 127.8, 127.6, 
127.0, 122.4, 78.4, 77.9, 76.2, 73.3, 73.0, 70.9, 70.5, 55.1, 40.1, 36.4, 36.2, 31.8, 31.3, 29.9, 29.8 (3C), 
28.7, 27.0, 26.1, 23.7, 23.1, 22.3, 22.2; HRMS (ESI+) Calc. for C41H61O5N4 [M+H]+ 689.4636, found 
689.4637. 
 
4.2.6 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)furan-2-carboxamide 18 
 
The general procedure was followed at a different scale. Thus, 8.00 mg EDCI.HCl (51.3 µmol) and 3.10 
mg DMAP (25.6 µmol) were combined with furan-2-carboxylic acid (5.70 mg, 51.3 µmol) followed by 
15.0 mg amine 15 (25.6 µmol). Purification by flash column chromatography (75% EtOAc/Hexane) 
provided amide 18 (12.0 mg, 69%), as a colourless oil. 
Rf 0.39 (75% EtOAc/Hexane);  –16 (c 0.86, CHCl3); IR (ATR) 3314, 2932, 2857, 1651, 1593 cm-
1; 1H NMR (500 MHz, CDCl3) δ 7.60 (1H, s, HAr), 7.41 (1H, dd, J = 1.7, 0.8 Hz, H21), 7.33-7.25 (5H, m, 
ArH), 7.09 (1H, dd, J = 3.5, 0.8 Hz, H19), 6.48 (1H, dd, J = 3.5, 1.7 Hz, H20), 6.37 (1H, br s, NH), 4.59 
(1H, dd, J = 11.0, 1.9 Hz, H1’), 4.48 (2H, s, OCH2Ar), 4.43 (1H, dd, J = 14.0, 3.4 Hz, H1a), 4.19 (1H, dd, 
J = 14.0, 8.1 Hz, H1b), 3.66-3.61 (1H, m, H2), 3.49-3.44 (1H, m, H5’), 3.46 (2H, t, J = 6.6 Hz, H9’), 3.42-
3.33 (6H, m, H10 + H11 + H16), 3.23-3.19 (1H, m, H6), 2.04-1.83 (3H, m, H3a’ + H4), 1.66-1.14 (29H, m, 
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H2’-4’ + H3b + H5 + H6’-8’ + H7-9 + H12-15); 13C NMR (125 MHz, CDCl3) δ 158.5, 150.0, 148.3, 143.8, 
138.8, 128.5, 127.8, 127.6, 122.4, 114.1, 112.2, 78.4, 77.8, 76.2, 73.3, 73.0, 70.9 (2C), 70.5, 55.1, 39.2, 
36.4, 36.2, 31.8, 31.3, 31.2, 29.9, 29.8 (2C), 28.7, 26.9, 26.1, 23.7, 23.1, 22.8, 22.3, 22.2; HRMS (ESI+) 
Calc. for C39H59O6N4 [M+H]+ 679.4429, found 679.4412. 
 
4.2.7 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)thiophene-2-carboxamide 19 
 
The general procedure was followed using thiophene-2-carboxylic acid (4.40 mg, 34.2 µmol). 
Purification by flash column chromatography (60% EtOAc/Hexane) provided amide 19 (10.0 mg, 84%), 
as a colourless oil. 
Rf 0.44 (70% EtOAc/Hexane);  –20 (c 0.84, CHCl3); IR (ATR) 3321, 2932, 2855, 1628, 1545, 
1512 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.60 (1H, s, HAr), 7.49 (1H, dd, J = 3.7, 1.0 Hz, H19), 7.44 
(1H, dd, J = 4.8, 1.0 Hz, H21), 7.33-7.25 (5H, m, ArH), 7.06 (1H, dd, J = 4.8, 3.7 Hz, H20), 6.12 (1H, br s, 
NH), 4.59 (1H, dd, J = 10.9, 1.8 Hz, H1’), 4.48 (2H, s, OCH2Ar), 4.43 (1H, dd, J = 14.0, 3.3 Hz, H1a), 
4.19 (1H, dd, J = 14.0, 8.1 Hz, H1b), 3.66-3.62 (1H, m, H2), 3.49-3.44 (1H, m, H5’), 3.46 (2H, t, J = 6.6 
Hz, H9’), 3.42-3.32 (6H, m, H10 + H11 + H16), 3.23-3.19 (1H, m, H6), 2.02-1.84 (3H, m, H3a’ + H4), 1.66-
1.13 (29H, m, H2’-4’ + H3b + H5 + H6’-8’ + H7-9 + H12-15); 13C NMR (125 MHz, CDCl3) δ 162.0, 149.9, 
139.3, 138.8, 129.8, 128.5, 127.9, 127.8, 127.7, 127.6, 122.4, 78.4, 77.9, 76.2, 73.3, 73.0, 70.9 (2C), 
70.5, 55.1, 40.1, 36.4, 36.2, 31.8, 31.3 (2C), 29.9, 29.8, 29.7 (2C), 28.8, 26.9, 26.1, 23.8, 23.1, 22.3, 
22.2; HRMS (ESI+) Calc. for C39H59O5N4S [M+H]+ 695.4201, found 695.4186. 
 
4.2.8 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-1H-pyrrole-2-carboxamide 20 
 
The general procedure was followed using pyrrole-2-carboxylic acid (3.80 mg, 34.2 µmol). Purification 
by flash column chromatography (60% EtOAc/Hexane) provided amide 20 (8.0 mg, 69%), as a 
colourless oil. 
Rf 0.26 (60% EtOAc/Hexane);  –18 (c 0.80, CHCl3); IR (ATR) 3238, 2932, 2855, 1717, 1626, 
1562, 1526 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.43 (1H, br s, NH), 7.61 (1H, s, HAr), 7.33-7.27 (5H, 
m, ArH), 6.90-6.89 (1H, m, H21), 6.54-6.53 (1H, m, H19), 5.96 (1H, q, J = 2.9 Hz, H20), 5.96 (1H, br s, 
NH), 4.59 (1H, dd, J = 10.9, 1.9 Hz, H1’), 4.49 (2H, s, OCH2Ar), 4.43 (1H, dd, J = 14.0, 3.3 Hz, H1a), 
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4.19 (1H, dd, J = 14.0, 8.1 Hz, H1b), 3.93 (3H, s, H22), 3.66-3.62 (1H, m, H2), 3.49-3.45 (1H, m, H5’), 
3.46 (2H, t, J = 6.6 Hz, H9’), 3.41-3.33 (6H, m, H10 + H11 + H16), 3.23-3.19 (1H, m, H6), 2.02-1.83 (3H, 
m, H3a’ + H4), 1.71-1.12 (29H, m, H2’-4’ + H3b + H5 + H6’-8’ + H7-9 + H12-15); 13C NMR (125 MHz, 
CDCl3) δ 161.1, 150.0, 138.8, 129.7, 128.5, 127.8, 127.6, 122.4, 121.3, 109.9, 108.5, 78.4, 77.9, 76.2, 
73.3, 73.0, 70.9, 70.8, 70.5, 55.1, 39.4, 36.4, 36.2, 31.8, 31.3 (2C), 30.0, 29.9, 29.8, 29.7, 28.8, 26.9, 
26.1, 23.8, 23.1, 22.3, 22.2; HRMS (ESI+) Calc. for C39H59O5N5Na [M+Na]+ 700.4408, found 700.4395. 
 
4.2.9 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-1-methyl-1H-pyrrole-2-carboxamide 
21 
 
The general procedure was followed using 1-methyl-2-pyrrolecarboxylic acid (4.30 mg, 34.2 µmol). 
Purification by flash column chromatography (55% EtOAc/Hexane) provided amide 21 (9.0 mg, 76%), 
as a colourless oil. 
Rf 0.41 (60% EtOAc/Hexane);  –17 (c 0.60, CHCl3); IR (ATR) 3335, 2932, 2851, 1717, 1636, 
1543, 1512 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.61 (1H, s, HAr), 7.35-7.27 (5H, m, ArH), 6.69 (1H, 
app t, J = 2.0 Hz, H21), 6.50 (1H, dd, J = 3.9, 1.7 Hz, H19), 6.06 (1H, dd, J = 3.9, 2.4 Hz, H20), 5.90 (1H, 
br s, NH), 4.59 (1H, dd, J = 11.0, 1.9 Hz, H1’), 4.49 (2H, s, OCH2Ar), 4.43 (1H, dd, J = 14.0, 3.3 Hz, 
H1a), 4.19 (1H, dd, J = 14.0, 8.0 Hz, H1b), 3.93 (3H, s, H22), 3.66-3.61 (1H, m, H2), 3.49-3.45 (1H, m, 
H5’), 3.46 (2H, t, J = 6.6 Hz, H9’), 3.38-3.32 (6H, m, H10 + H11 + H16), 3.22-3.19 (1H, m, H6), 2.03-1.84 
(3H, m, H3a’ + H4), 1.69-1.13 (29H, m, H2’-4’ + H3b + H5 + H6’-8’ + H7-9 + H12-15); 13C NMR (125 MHz, 
CDCl3) δ 162.1, 149.9, 138.8, 129.7, 128.5, 127.8, 127.7, 127.6, 122.4, 111.2, 107.2, 78.4, 77.9, 76.2, 
73.3, 73.0, 71.0, 70.9, 70.5, 55.1, 39.3, 36.8, 36.4, 36.2, 31.9, 31.4, 31.3, 30.0, 29.9, 29.8 (2C), 28.7, 
27.0, 26.1, 23.8, 23.1, 22.3, 22.2; HRMS (ESI+) Calc. for C40H61O5N5Na [M+Na]+ 714.4565, found 
714.4549. 
 
4.2.10 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)furan-3-carboxamide 22 
 
The general procedure was followed using furan-3-carboxylic acid (3.80 mg, 34.2 µmol). Purification by 
flash column chromatography (70% EtOAc/Hexane) provided amide 22 (10.0 mg, 86%), as a colourless 
oil. 
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Rf 0.29 (70% EtOAc/Hexane);  –15 (c 0.97, CHCl3); IR (ATR) 3300, 2932, 2855, 1636, 1587, 
1572, 1537 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.92 (1H, dd, J = 1.3, 0.8 Hz, H18), 7.60 (1H, s, HAr), 
7.41 (1H, app t, J = 1.6 Hz, H21), 7.34-7.25 (5H, m, ArH), 6.61 (1H, dd, J = 1.8, 0.8 Hz, H20), 6.00 (1H, 
br s, NH), 4.59 (1H, dd, J = 10.9, 1.9 Hz, H1’), 4.48 (2H, s, OCH2Ar), 4.42 (1H, dd, J = 14.0, 3.3 Hz, 
H1a), 4.18 (1H, dd, J = 14.0, 8.1 Hz, H1b), 3.66-3.61 (1H, m, H2), 3.49-3.44 (1H, m, H5’), 3.45 (2H, t, J = 
6.6 Hz, H9’), 3.40-3.31 (6H, m, H10 + H11 + H16), 3.22-3.19 (1H, m, H6), 2.02-1.84 (3H, m, H3a’ + H4), 
1.72-1.12 (29H, m, H2’-4’ + H3b + H5 + H6’-8’ + H7-9 + H12-15); 13C NMR (125 MHz, CDCl3) δ 162.7, 
149.9, 144.7, 143.8, 138.7, 128.5, 127.8, 127.6, 122.9, 122.4, 108.4, 78.4, 77.9, 76.2, 73.3, 73.0, 70.9, 
70.8, 70.5, 55.1, 39.6, 36.4, 36.2, 31.8, 31.3 (2C), 29.9, 29.8 (3C), 28.8, 26.9, 26.1, 23.7, 23.1, 22.4, 
22.3; HRMS (ESI+) Calc. for C39H58O6N4Na [M+Na]+ 701.4249, found 701.4229.  
 
4.2.11 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)thiophene-3-carboxamide 23 
 
The general procedure was followed using thiophene-3-carboxylic acid (4.40 mg, 34.2 µmol). 
Purification by flash column chromatography (60% EtOAc/Hexane) provided amide 23 (11.0 mg, 92%), 
as a colourless oil. 
Rf 0.38 (70% EtOAc/Hexane);  –13 (c 1.1, CHCl3); IR (ATR) 3318, 2932, 2855, 1715, 1634, 1545, 
1508 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.85 (1H, dd, J = 2.9, 1.2 Hz, H18), 7.61 (1H, s, HAr), 7.38 
(1H, dd, J = 5.0, 1.2 Hz, H21), 7.33-7.25 (6H, m, H20 + ArH), 6.11 (1H, br s, NH), 4.59 (1H, dd, J = 10.9, 
1.8 Hz, H1’), 4.48 (2H, s, OCH2Ar), 4.43 (1H, dd, J = 14.0, 3.3 Hz, H1a), 4.19 (1H, dd, J = 14.0, 8.1 Hz, 
H1b), 3.66-3.62 (1H, m, H2), 3.49-3.44 (1H, m, H5’), 3.46 (2H, t, J = 6.6 Hz, H9’), 3.42-3.32 (6H, m, H10 
+ H11 + H16), 3.23-3.19 (1H, m, H6), 2.02-1.86 (3H, m, H3a’ + H4), 1.69-1.12 (29H, m, H2’-4’ + H3b + H5 + 
H6’-8’ + H7-9 + H12-15); 13C NMR (125 MHz, CDCl3) δ 163.2, 149.9, 138.8, 137.9, 128.5, 128.1, 127.8, 
127.6, 126.5, 126.1, 122.5, 78.4, 77.9, 76.2, 73.3, 73.0, 70.9, 70.8, 70.5, 55.1, 39.9, 36.4, 36.2, 31.8, 
31.3 (2C), 29.9, 29.8 (2C), 29.7, 28.8, 26.9, 26.1, 23.8, 23.1, 22.3, 22.2; HRMS (ESI+) Calc. for 
C39H58O5N4SNa [M+Na]+ 717.4020, found 717.4008.  
 
4.2.12 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)thiazole-4-carboxamide 24 
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The general procedure was followed using 1,3-thiazole-4-carboxylic acid (4.40 mg, 34.2 µmol). 
Purification by flash column chromatography (75% EtOAc/Hexane) provided amide 24 (9.8 mg, 82%), 
as a colourless oil. 
Rf 0.23 (70% EtOAc/Hexane);  –19 (c 0.72, CHCl3); IR (ATR) 3361, 3064, 2932, 2851, 1647, 
1541 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.73 (1H, d, J = 2.1 Hz, H20), 8.15 (1H, d, J = 2.1 Hz, H19), 
7.60 (1H, s, HAr), 7.39 (1H, br s, NH), 7.35-7.24 (5H, m, ArH), 4.59 (1H, dd, J = 10.9, 1.8 Hz, H1’), 4.48 
(2H, s, OCH2Ar), 4.43 (1H, dd, J = 14.0, 3.4 Hz, H1a), 4.19 (1H, dd, J = 14.0, 8.0 Hz, H1b), 3.66-3.61 
(1H, m, H2), 3.49-3.42 (5H, m, H16 + H5’ + H9’), 3.38-3.34 (4H, m, H10 + H11), 3.23-3.19 (1H, m, H6), 
2.02-1.83 (3H, m, H3a’ + H4), 1.66-1.12 (29H, m, H2’-4’ + H3b + H5 + H6’-8’ + H7-9 + H12-15); 13C NMR 
(125 MHz, CDCl3) δ 161.0, 152.7, 151.4, 150.0, 138.8, 128.5, 127.8, 127.6, 123.1, 122.4, 78.4, 77.8, 
76.2, 73.3, 73.0, 71.0, 70.9, 70.5, 55.1, 39.4, 36.4, 36.2, 31.8, 31.3, 31.2, 29.9, 29.8 (2C), 29.7, 28.7, 
27.0, 26.1, 23.7, 23.1, 22.3, 22.2; HRMS (ESI+) Calc. for C38H58O5N5S [M+H]+ 696.4153, found 
696.4126.  
 
4.2.13 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)oxazole-4-carboxamide 25 
 
The general procedure was followed using 1,3-oxazole-4-carboxylic acid (3.90 mg, 34.2 µmol) and 
DMF (2 mL) as solvent. Purification by flash column chromatography (75% EtOAc/Hexane) provided 
amide 25 (5.5 mg, 47%), as a colourless oil. 
Rf 0.26 (75% EtOAc/Hexane);  –21 (c 0.50, CHCl3); IR (ATR) 3335, 2934, 2857, 1661, 1595, 
1514 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.21 (1H, d, J = 1.0 Hz, H19), 7.84 (1H, d, J =1.0 Hz, H20), 
7.60 (1H, s, HAr), 7.35-7.24 (5H, m, ArH), 6.92 (1H, br s, NH), 4.59 (1H, dd, J = 10.9, 1.9 Hz, H1’), 4.49 
(2H, s, OCH2Ar), 4.43 (1H, dd, J = 14.0, 3.4 Hz, H1a), 4.19 (1H, dd, J = 14.0, 8.0 Hz, H1b), 3.67-3.61 
(1H, m, H2), 3.50-3.44 (3H, m, H5’ + H9’), 3.43-3.33 (6H, m, H10 + H11+ H16), 3.24-3.19 (1H, m, H6), 
2.03-1.83 (3H, m, H3a’ + H4), 1.63-1.14 (29H, m, H2’-4’ + H3b + H5 + H6’-8’ + H7-9 + H12-15); 13C NMR 
(100 MHz, CDCl3) δ 160.3, 150.6, 150.0, 141.3, 138.8, 136.2, 128.5, 127.8, 127.6, 122.4, 78.4, 77.9, 
76.2, 73.3, 73.0, 71.0 (2C), 70.5, 55.1, 39.1, 36.4, 36.2, 31.9, 31.4, 31.3, 29.9, 29.8, 29.7, 28.8 (2C), 26.9, 
26.1, 23.8, 23.1, 22.3, 22.3; HRMS (ESI+) Calc. for C38H57O6N5Na [M+Na]+ 702.4201, found 702.4182. 
 
4.2.14 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-2-methyloxazole-4-carboxamide 26 
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 The general procedure was followed using 2-methyl-1,3-oxazole-4-carboxylic acid (4.30 mg, 34.2 
µmol). Purification by flash column chromatography (75% EtOAc/Hexane) provided amide 26 (9.6 mg, 
81%), as a colourless oil. 
Rf 0.23 (75% EtOAc/Hexane);  –15 (c 0.96, CHCl3); IR (ATR) 3362, 2932, 2855, 1668, 1647, 
1607, 1518 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.05 (1H, s, H19), 7.60 (1H, s, HAr), 7.35-7.24 (5H, m, 
ArH), 6.86 (1H, br s, NH), 4.59 (1H, dd, J = 10.8, 1.8 Hz, H1’), 4.48 (2H, s, OCH2Ar), 4.43 (1H, dd, J = 
14.0, 3.4 Hz, H1a), 4.19 (1H, dd, J = 14.0, 8.0 Hz, H1b), 3.66-3.61 (1H, m, H2), 3.50-3.44 (1H, m, H5’), 
3.46 (1H, t, J = 6.6 Hz, H9’), 3.41-3.34 (6H, m, H10 + H11 + H16), 3.24-3.19 (1H, m, H6), 2.46 (3H, s, 
H21), 2.04-1.83 (3H, m, H3a’ + H4), 1.66-1.12 (29H, m, H2’-4’ + H3b + H5 + H6’-8’ + H7-9 + H12-15); 13C 
NMR (125 MHz, CDCl3) δ 161.4, 160.8, 150.0, 140.8, 138.8, 136.4, 128.5, 127.8, 127.6, 122.4, 78.4, 
77.8, 76.2, 73.3, 73.0, 71.0, 70.9, 70.5, 55.1, 39.1, 36.4, 36.2, 31.8, 31.3, 31.2, 29.9, 29.8 (2C), 29.7, 
28.7, 26.9, 26.1, 23.7, 23.1, 22.3, 22.2, 14.0; HRMS (ESI+) Calc. for C39H60O6N5 [M+H]+ 694.4538, 
found 694.4514.  
 
4.2.15 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-1-methyl-1H-pyrazole-5-
carboxamide 27 
 
The general procedure was followed at a different scale. Thus, 8.00 mg EDCI.HCl (51.3 µmol) and 3.10 
mg DMAP (25.6 µmol) were combined with 2-methyl-2H-pyrazole-3-carboxylic acid (6.50 mg, 51.3 
µmol) followed by 15.0 mg amine 15 (25.6 µmol). Purification by flash column chromatography (75% 
EtOAc/Hexane) provided amide 27 (12.0 mg, 68%), as a colourless oil. 
Rf 0.29 (75% EtOAc/Hexane);  –13 (c 0.45, CHCl3); IR (ATR) 3323, 2934, 2857, 1724, 1661, 
1543 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.60 (1H, s, HAr), 7.42 (1H, d, J = 2.1 Hz, H19), 7.33-7.27 
(5H, m, ArH), 6.49 (1H, d, J = 2.1 Hz, H20), 6.18 (1H, br s, NH), 4.59 (1H, dd, J = 11.0, 1.9 Hz, H1’), 
4.48 (2H, s, OCH2Ar), 4.42 (1H, dd, J = 14.0, 3.3 Hz, H1a), 4.19 (1H, dd, J = 14.0, 8.1 Hz, H1b), 4.17 
(3H, s, H21), 3.66-3.62 (1H, m, H2), 3.49-3.44 (1H, m, H5’), 3.46 (2H, t, J = 6.6 Hz, H9’), 3.39-3.33 (6H, 
m, H10 + H11 + H16), 3.22-3.19 (1H, m, H6), 2.04-1.91 (3H, m, H3a’ + H4), 1.69-1.15 (29H, m, H2’-4’ + H3b 
+ H5 + H6’-8’ + H7-9 + H12-15); 13C NMR (125 MHz, CDCl3) δ 160.1, 150.0, 138.7, 137.7, 135.6, 128.5, 
127.8, 127.6, 122.4, 106.2, 78.4, 77.9, 76.2, 73.3, 73.0, 70.9, 70.8, 70.5, 55.1, 39.6, 39.4, 36.4, 36.2, 
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31.8, 31.3 (2C), 29.9, 29.8, 29.7 (2C), 28.8, 26.9, 26.1, 23.7, 23.1, 22.3, 22.2; HRMS (ESI+) Calc. for 
C39H61O5N6 [M+H]+ 693.4698, found 693.4681. 
 
4.2.16 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-5-methylfuran-2-carboxamide 28 
 
The general procedure was followed using 5-methyl-furan-2-carboxylic acid (4.30 mg, 34.2 µmol). 
Purification by flash column chromatography (75% EtOAc/Hexane) provided amide 28 (8.1 mg, 67%), 
as a colourless oil. 
Rf 0.34 (75% EtOAc/Hexane);  –17 (c 0.81, CHCl3); IR (ATR) 3298, 2932, 2857, 1717, 1647, 
1609, 1555 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.60 (1H, s, HAr), 7.33-7.24 (5H, m, ArH), 6.98 (1H, d, 
J = 3.3 Hz, H19), 6.27 (1H, br s, NH), 6.08 (1H, d, J = 3.3 Hz, H20), 4.59 (1H, dd, J = 10.9, 1.9 Hz, H1’), 
4.49 (2H, s, OCH2Ar), 4.43 (1H, dd, J = 14.0, 3.4 Hz, H1a), 4.19 (1H, dd, J = 14.0, 8.0 Hz, H1b), 3.66-
3.61 (1H, m, H2), 3.50-3.44 (1H, m, H5’), 3.46 (2H, t, J = 6.6 Hz, H9’), 3.41-3.34 (6H, m, H10 + H11 + 
H16), 3.23-3.19 (1H, m, H6), 2.33 (3H, s, H22), 2.03-1.83 (3H, m, H3a’ + H4), 1.64-1.12 (29H, m, H2’-4’ + 
H3b + H5 + H6’-8’ + H7-9 + H12-15); 13C NMR (100 MHz, CDCl3) δ 158.7, 154.3, 150.0, 146.7, 138.8, 128.5, 
127.8, 127.6, 122.4, 115.3, 108.6, 78.4, 77.9, 76.2, 73.3, 73.0, 71.0, 70.9, 70.5, 55.1, 39.1, 36.4, 36.2, 
31.9, 31.4, 31.3, 30.0, 29.9, 29.8 (2C), 28.8, 26.9, 26.1, 23.8, 23.1, 22.4, 22.3, 14.0; HRMS (ESI+) Calc. 
for C40H60O6N4Na [M+Na]+ 715.4405, found 715.4389. 
 
4.2.17 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-3-methylfuran-2-carboxamide 29 
 
The general procedure was followed using 3-methyl-furan-2-carboxylic acid (4.30 mg, 34.2 µmol). 
Purification by flash column chromatography (50% EtOAc/Hexane) provided amide 29 (10.6 mg, 90%), 
as a colourless oil. 
Rf 0.41 (60% EtOAc/Hexane);  –15 (c 0.96, CHCl3); IR (ATR) 2916, 2849, 1734, 1651, 1612, 
1526 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.60 (1H, s, HAr), 7.33-7.25 (6H, m, H22 + ArH), 6.33 (1H, br 
s, NH), 6.31 (1H, d, J = 1.6 Hz, H21), 4.59 (1H, dd, J = 10.8, 1.9 Hz, H1’), 4.48 (2H, s, OCH2Ar), 4.43 
(1H, dd, J = 14.0, 3.3 Hz, H1a), 4.19 (1H, dd, J = 14.0, 8.0 Hz, H1b), 3.67-3.60 (1H, m, H2), 3.50-3.44 
(1H, m, H5’), 3.46 (2H, t, J = 6.6 Hz, H9’), 3.40-3.33 (6H, m, H10 + H11 + H16), 3.23-3.18 (1H, m, H6), 
2.39 (3H, s, H20), 2.04-1.83 (3H, m, H3a’ + H4), 1.67-1.12 (29H, m, H2’-4’ + H3b + H5 + H6’-8’ + H7-9 + H12-
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15); 13C NMR (100 MHz, CDCl3) δ 159.8, 150.0, 142.5, 142.1, 138.8, 128.5, 127.8, 127.6, 127.3, 122.4, 
115.5, 78.4, 77.9, 76.2, 73.3, 73.0, 71.0, 70.9, 70.5, 55.1, 38.9, 36.4, 36.2, 31.9, 31.4, 31.3, 29.9 (2C), 
29.8 (2C), 28.8, 27.0, 26.1, 23.8, 23.1, 22.4, 22.3, 11.2; HRMS (ESI+) Calc. for C40H60O6N4Na 
[M+Na]+ 715.4405, found 715.4388. 
 
4.2.18 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-4,5-dimethylfuran-2-carboxamide 30 
 
The general procedure was followed using 4,5-dimethylfuran-2-carboxylic acid (4.80 mg, 34.2 µmol). 
Purification by flash column chromatography (60% EtOAc/Hexane) provided amide 30 (7.6 mg, 63%), 
as a colourless oil. 
Rf 0.29 (60% EtOAc/Petrol);  –19 (c 0.73, CHCl3); IR (ATR) 3310, 2932, 2857, 1717, 1645, 1564 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.60 (1H, s, HAr), 7.33-7.28 (5H, m, ArH), 6.86 (1H, d, J = 3.3 Hz, 
H19), 6.23 (1H, br s, NH), 4.59 (1H, dd, J = 10.8, 1.7 Hz, H1’), 4.48 (2H, s, OCH2Ar), 4.43 (1H, dd, J = 
14.0, 3.4 Hz, H1a), 4.19 (1H, dd, J = 14.0, 8.0 Hz, H1b), 3.66-3.61 (1H, m, H2), 3.50-3.44 (1H, m, H5’), 
3.46 (2H, t, J = 6.6 Hz, H9’), 3.40-3.34 (6H, m, H10 + H11 + H16), 3.24-3.18 (1H, m, H6), 2.23 (3H, s, H23), 
2.04-1.83 (3H, m, H3a’ + H4), 1.95 (3H, s, H21), 1.65-1.14 (29H, m, H2’-4’ + H3b + H5 + H6’-8’ + H7-9 + H12-
15); 13C NMR (100 MHz, CDCl3) δ 158.8, 150.0, 149.9, 145.3, 138.8, 128.5, 127.8, 127.6, 122.4, 117.4, 
117.1, 78.4, 77.9, 76.2, 73.3, 73.0, 71.0, 70.9, 70.5, 55.1, 39.1, 36.4, 36.2, 31.9, 31.4, 31.3, 29.9 (2C), 
29.8 (2C), 28.8, 26.9, 26.1, 23.8, 23.1, 22.3, 22.2, 11.8, 9.9; HRMS (ESI+) Calc. for C41H62O6N4Na 
[M+Na]+ 729.4562, found 729.4560. 
 
4.2.19 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-5-chlorofuran-2-carboxamide 31 
 
The general procedure was followed using 5-chlorofuran-2-carboxylic acid (5.00 mg, 34.2 µmol). 
Purification by flash column chromatography (45% EtOAc/Hexane) provided amide 31 (6.8 mg, 56%), 
as a colourless oil. 
Rf 0.34 (60% EtOAc/Petrol);  –16 (c 0.65, CHCl3); IR (ATR) 3300, 2934, 2857, 1717, 1647, 1599, 
1533 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.60 (1H, s, HAr), 7.33-7.24 (5H, m, ArH), 7.07 (1H, d, J = 
3.5 Hz, H19), 6.28 (1H, d, J = 3.5 Hz, H20), 6.27 (1H, br s, NH), 4.59 (1H, dd, J = 10.9, 1.9 Hz, H1’), 
4.49 (2H, s, OCH2Ar), 4.43 (1H, dd, J = 14.0, 3.4 Hz, H1a), 4.19 (1H, dd, J = 14.0, 8.0 Hz, H1b), 3.66-
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3.62 (1H, m, H2), 3.50-3.44 (1H, m, H5’), 3.46 (2H, t, J = 6.6 Hz, H9’), 3.41-3.34 (6H, m, H10 + H11 + 
H16), 3.24-3.19 (1H, m, H6), 2.03-1.80 (3H, m, H3a’ + H4), 1.66-1.14 (29H, m, H2’-4’ + H3b + H5 + H6’-8’ + 
H7-9 + H12-15); 13C NMR (100 MHz, CDCl3) δ 157.4, 150.0, 147.4, 138.8, 138.2, 128.5, 127.8, 127.6, 
122.4, 116.2, 109.2, 78.4, 77.9, 76.3, 73.4, 73.0, 70.9 (2C), 70.5, 55.1, 39.3, 36.4, 36.2, 31.9, 31.4, 31.3, 
30.0, 29.9, 29.8, 29.7, 28.8, 26.9, 26.1, 23.8, 23.1, 22.4, 22.3; HRMS (ESI+) Calc. for C39H57O6N4ClNa 
[M+Na]+ 735.3859, found 735.3843. 
 
4.2.20 N-(6-(4-((2S,6S)-6-((4-((2S,6S)-6-(4-(benzyloxy)butyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-
triazol-1-yl)methyl)tetrahydro-2H-pyran-2-yl)butoxy)hexyl)-5-nitrofuran-2-carboxamide 32 
 
The general procedure was followed using 5-nitrofuran-2-carboxylic acid (5.40 mg, 34.2 µmol). 
Purification by flash column chromatography (20% Acetone/Hexane) provided amide 32 (3.5 mg, 28%), 
as a colourless oil. 
Rf 0.35 (60% EtOAc/Hexane);  –15 (c 0.55, CHCl3); IR (ATR) 3296, 2932, 2855, 1717, 1668, 
1553 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.60 (1H, s, HAr), 7.35 (1H, d, J = 3.8 Hz, H19), 7.33-7.27 
(5H, m, ArH), 7.24 (1H, d, J = 3.8 Hz, H20), 6.69 (1H, br s, NH), 4.59 (1H, dd, J = 11.0, 1.9 Hz, H1’), 
4.49 (2H, s, OCH2Ar), 4.43 (1H, dd, J = 14.0, 3.4 Hz, H1a), 4.19 (1H, dd, J = 14.0, 8.1 Hz, H1b), 3.66-
3.63 (1H, m, H2), 3.49-3.41 (3H, m, H5’ + H16), 3.46 (2H, t, J = 6.6 Hz, H9’), 3.41-3.34 (4H, m, H10 + 
H11), 3.23-3.19 (1H, m, H6), 2.04-1.80 (3H, m, H3a’ + H4), 1.66-1.13 (29H, m, H2’-4’ + H3b + H5 + H6’-8’ + 
H7-9 + H12-15); 13C NMR (125 MHz, CDCl3) δ 156.4, 151.5, 150.0, 148.4, 138.8, 128.5, 127.8, 127.6, 
122.4, 115.9, 112.7, 78.4, 77.9, 76.2, 73.3, 73.0, 70.9, 70.8, 70.5, 55.1, 39.7, 36.4, 36.2, 31.9, 31.3, 29.9, 
29.8, 29.7, 29.6, 28.8, 26.9, 26.0, 23.8, 23.1, 22.3, 22.2; HRMS (ESI+) Calc. for C39H57O8N5Na 
[M+Na]+ 746.4099, found 746.4085. 
 
4.2.21 N-(6-methoxyhexyl)furan-2-carboxamide 33 
 
To a solution of N-(6-hydroxyhexyl)-1-methyl-1H-pyrazole-5-carboxamide S9 (10.0 mg, 4.44 µmol) 
and 1,8-bis(dimethylamino)naphthalene (32.9 mg, 221 µmol) in dry CH2Cl2 (2 mL) at 0 °C was added 
trimethyloxonium tetrafluoroborate (47.4 mg, 221 µmol) and the mixture stirred at RT for 72 h. The 
mixture was cooled to 0 °C and reaction quenched with saturated NH4OH solution (0.5 mL). Saturated 
NaHCO3 solution (5 mL) was added and the organics extracted with CH2Cl2 (3 x 5 mL). The combined 
organic extracts were washed with 0.3N HCl solution, dried (MgSO4), filtered and concentrated in 
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vacuo Purification by flash column chromatography (65% EtOAc/Hexane) provided ether 33 (5.5 mg, 
52%), as a colourless oil. 
Rf 0.34 (75% EtOAc/Hexane); IR (ATR) 3310, 2930, 2858, 1645, 1543 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 7.43 (1H, d, J = 1.8 Hz, H10), 6.46 (1H, d, J = 1.8 Hz, H11), 6.01 (1H, br s, NH), 4.17 (3H, s, 
H12), 3.41-3.36 (4H, m, H2 + H7), 3.32 (3H, s, H1), 1.63-1.57 (4H, m, H3 + H6), 1.41-1.38 (4H, m, H4 + 
H5); 13C NMR (125 MHz, CDCl3) δ 160.1, 137.7, 135.5, 106.0, 72.8, 58.7, 39.6, 39.4, 29.7, 29.6, 26.9, 
26.0; HRMS (ESI+) Calc. for C12H21O3N2Na [M+Na]+ 262.1526, found 262.1526. 
 
4.2.22 N-(6-methoxyhexyl)furan-2-carboxamide 34 
 
To a solution of N-(6-hydroxyhexyl)furan-2-carboxamide S10 (8.00 mg, 37.9 µmol) and 1,8-
bis(dimethylamino)naphthalene (81.0 mg, 379 µmol) in dry CH2Cl2 (2 mL) at 0 °C was added 
trimethyloxonium tetrafluoroborate (56.0 mg, 379 µmol) and the mixture stirred at RT for 72 h. The 
mixture was cooled to 0 °C and reaction quenched with saturated NH4OH solution (0.5 mL). Saturated 
NaHCO3 solution (5 mL) was added and the organics extracted with Et2O (3 x 5 mL). The combined 
organic extracts were washed with 1N HCl solution, dried (MgSO4), filtered and concentrated in vacuo 
Purification by flash column chromatography (40% EtOAc/Petrol) provided ether 34 (7.6 mg, 89%), as 
a colourless oil. 
Rf 0.36 (50% EtOAc/Petrol); IR (ATR) 3302, 2930, 2859, 1643, 1593, 1572, 1530 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.42 (1H, dd, J = 1.8, 0.8 Hz, H12), 7.09 (1H, dd, J = 3.5, 0.8 Hz, H10), 6.48 (1H, dd, J = 
3.5, 1.8 Hz, H11), 6.35 (1H, br s, NH), 3.41 (2H, app q, J = 6.9 Hz, H7), 3.35 (2H, t, J = 6.5 Hz, H2), 3.32 
(3H, s, H1), 1.62-1.54 (4H, m, H3 + H6), 1.41-1.37 (4H, m, H4 + H5); 13C NMR (100 MHz, CDCl3) δ 
158.5, 148.3, 143.8, 114.1, 112.2, 72.9, 58.7, 39.2, 29.8, 29.7, 26.9, 26.0; HRMS (ESI+) Calc. for 
C12H19O3NNa [M+Na]+ 248.1257, found 248.1254. 
 
4.2.23 N-(6-methoxyhexyl)-5-nitrofuran-2-carboxamide 35 
 
To a solution of N-(6-hydroxyhexyl)-5-nitrofuran-2-carboxamide S11 (9.70 mg, 37.9 µmol) and 1,8-
bis(dimethylamino)naphthalene (81.0 mg, 379 µmol) in dry CH2Cl2 (2 mL) at 0 °C was added 
trimethyloxonium tetrafluoroborate (56.0 mg, 379 µmol) and the mixture stirred at RT for 72 h. The 
mixture was cooled to 0 °C and reaction quenched with saturated NH4OH solution (0.5 mL). Saturated 
NaHCO3 solution (5 mL) was added and the organics extracted with Et2O (3 x 5 mL). The combined 
organic extracts were washed with 1N HCl solution, dried (MgSO4), filtered and concentrated in vacuo 
Purification by flash column chromatography (30% EtOAc/Petrol) provided ether 35 (3.3 mg, 32%), as 
a colourless oil. 
Rf 0.50 (50% EtOAc/Petrol); IR (ATR) 3300, 2932, 2859, 1653, 1584, 1553, 1528 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.36 (1H, d, J = 3.8 Hz, H10), 7.25 (1H, d, J = 3.8 Hz, H11), 6.61 (1H, br s, NH), 3.45 
(2H, app q, J = 7.0 Hz, H7), 3.37 (2H, t, J = 6.5 Hz, H2), 3.33 (3H, s, H1), 1.66-1.57 (4H, m, H3 + H6), 
1.42-1.39 (4H, m, H4 + H5); 13C NMR (100 MHz, CDCl3) δ 156.3, 148.4, 115.9, 112.6, 72.8, 58.7, 39.7, 
29.6, 29.6, 26.9, 26.0; HRMS (ESI+) Calc. for C12H18O5N2Na [M+Na]+ 293.1108, found 293.1104. 
 
4.3 Biological Testing 
 
4.3.1 Cell culture 
 
Bloodstream form T. brucei brucei strain 427 were grown in HMI-9 media supplemented with 10% 
foetal bovine serum (Gibco) and 2.5 µg/mL G418 (Calbiochem) at 37°C with 5% v/v CO2 with 10% 
bovine serum and G418 (2.5 µg/mL) at 37°C with 5% v/v CO2, as described elsewhere.8 Procyclic form 
T. brucei brucei strain 29-13 were grown in SDM-79 media (Gibco) supplemented with 2g/L sodium 
bicarbonate (Fisher Scientific), 7.5 µg/mL haemin (Sigma) 10% foetal bovine serum, 12.5 µg/mL G418 
and 25 µg/mL hygromycin (Formedium) at 27.5°C with 5% v/v CO2.  
HeLa cells (ATCC® CCL-2) and African Green monkey kidney Vero cells (ECACC 84113001) were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM, Sigma) supplemented with 10% foetal bovine 
serum and grown at 37 °C in 5% CO2 atmosphere. 
Epimastigote Trypanosoma cruzi CL Brener strain were grown at 28 °C in RPMI 1640 medium (Sigma) 
supplemented with 20 mM HEPES pH 7.2 (Sigma), 4.9 mg/mL tryptone (Sigma), PGAB (2 mM sodium 
glutamate, 2 mM sodium pyruvate, 100 µg/mL streptomycin and 100 U/mL penicillin, all Sigma), 20 
µg/mL haemin and 10% heat-inactivated foetal bovine serum.   
Promastigote L. major MHOM/IL/80/Friedlin were grown at 28 °C in M199 media (Sigma) pH 7.4, 
supplemented with 40 mM HEPES pH 7.4, 100 µM adenosine, 5 µg/mL haemin and 10% heat-
inactivated foetal bovine serum.   
 
4.3.2 Cytotoxicity assays 
 
The determination of the EC50 of the compounds using Alamar Blue was completed as previously 
described.29 Briefly, compounds were made up in DMSO and two-fold serial dilutions of compound in 
media were carried out in a 96-well plate in quadruplicate.  Cells were counted using CASY Cell 
Counter and seeded as specified below. 
Bloodstream form parasites, procyclic form parasites and HeLa cells were plated out at 1x103 cells/well, 
1x104 cells/well and 1x103 cells/well, respectively. After 64 hours (3 days) Alamar Blue was added to 
each well and left for 6-8 hours to develop.  
Mid-log L. major were diluted in media and seeded at 2 x105 per well in 100 µL media.  Negative 
controls of DMSO only were included.  Plates were incubated at 28 °C for 72 hours, after which 20 µL 
Alamar Blue (12.5 mg resazurin salt in 100 mL PBS) was added to all wells and incubated for a further 
6 hours.   
Mid-log T. cruzi were diluted in media and seeded at 5 x105 per well in 100 µL media.  Negative 
controls of DMSO only and positive control of nifurtimox were included.  Plates were incubated at 
28 °C for 72 hours, after which 10 µL Alamar Blue was added to all wells and incubated for a further 6 
hours. 
For Vero cell assays, the monolayer was trypsinized, diluted in media and cells were seeded at 4 x103 
cells per well.  Cells were incubated at 37 °C with 5% CO2 for 24 hours to allow attachment, after which 
media was removed and replaced with fresh media containing serial dilutions of compound. Drug 
diluted in media was added and plates were incubated for 72 hours, after which 10 µL Alamar Blue was 
added to all wells and incubated for a further 2 hours. 
Cell viability was quantified using an FLx 800 plate reader (BioTek) with excitation wavelength 540/35 
nm and emission wavelength at 590/10 nm using Gen5 Reader Control 2.0 Software (BioTek). EC50 
values were determined using a 4-parameter logistic regression equation using GraFit 5.0 (Erithacus 
Software).  
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